Maxim Group Reiterates Buy on Capricor Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy has reiterated a Buy rating on Capricor Therapeutics (NASDAQ:CAPR) and maintained a $12 price target.
September 17, 2024 | 5:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Maxim Group's analyst Jason McCarthy has reiterated a Buy rating for Capricor Therapeutics, maintaining a $12 price target. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $12 price target by Maxim Group indicates a positive outlook on Capricor Therapeutics' stock. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100